|

SBRT With Atezo/Bev for HCC

RECRUITINGPhase 1Sponsored by Abramson Cancer Center at Penn Medicine
Actively Recruiting
PhasePhase 1
SponsorAbramson Cancer Center at Penn Medicine
Started2022-09-01
Est. completion2026-12-31
Eligibility
Age18 Years – 99 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT05488522

Summary

A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)

Eligibility

Age: 18 Years – 99 YearsHealthy volunteers accepted
Inclusion Criteria:

* Subjects must have hepatocellular carcinoma (HCC) that is not amenable to curative-intent surgical or ablation (where surgery or ablation are not indicated due to disease extent, co-morbidities, or other technical reasons) and systemic therapy is indicated.

Exclusion Criteria:

\-

Conditions4

CancerHepatocellular CarcinomaLiver CancerLiver Disease

Locations1 site

Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104-4283
Clinical Trials Office - Abramson Cancer Center800-474-9892

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.